Biography
William Audeh, MD, MS, Chief Medical Officer at Agendia, is a medical oncologist specializing in breast cancer, with nearly 30 years of experience as a clinician and clinical researcher at the Cedars-Sinai Cancer Center in Los Angeles. Prior to joining Agendia, and in addition to his clinical practice, he served as the former Director of the Cedars-Sinai Cancer Center and Medical Director of the Wasserman Breast Cancer Risk Reduction Program. Dr. Audeh has been Principal Investigator on a wide variety of national and international clinical and translational trials, and has authored numerous publications in the field of breast cancer, cancer genomics and targeted cancer therapy.

Genomic Profiling Showcase:
Agendia
Agendia is a leading precision oncology company that develops genomic tests to help physicians navigate the complexities within breast cancer. Together, MammaPrint® and BluePrint® provide a comprehensive genomic profile to help patients make informed treatment decisions. Learn more: www.agendia.com

Expanding Clinical Utility for Genomic Profiling in Early-Stage Breast Cancer
This presentation will empower you with data demonstrating the utility of Agendia’s assays, MammaPrint® and BluePrint®, for patients with breast cancer. Review the latest data and learn about the real-world impact of MammaPrint and BluePrint. Please join us for an informative, interactive session.

Biography
Alif is a pioneer in using network science and artificial intelligence to solve some of the most difficult challenges in healthcare. As the CEO of Scipher Medicine, he is pioneering the development of technologies to match each patient with their most effective therapy. Concerned by the healthcare system’s inability to prescribe the right drugs to the right patients, Alif and his team are developing and commercializing precision diagnostics and therapeutics in autoimmune diseases. With a unique global perspective on healthcare, Alif has led cross-disciplinary teams throughout Asia, Europe, and the Americas and raised more than $350 million in venture and private equity capital to bring novel technologies to market. Through Alif’s leadership, entrepreneurial spirit, and scientific expertise, Scipher will continue to leverage AI and network medicine to continue improving healthcare utilization and patient outcomes.

Genomic Profiling Showcase:
Scipher Medicine
Scipher Medicine is a precision immunology company matching each patient with their most effective therapy.

Biography
Jongmin is passionate about identifying cis-regulatory modules (CRMs) and applying CRMs to understand and engineer cellular states. While a postdoc at Caltech, he pioneered the use of barcoded reporters for high-throughput CRM discovery in sea urchin embryos. As an independent PI at Rutgers, his lab focused on developing high-throughput reporter assays: MMOSAIC that enabled high-throughput spatial analysis of cis-regulatory modules in embryos without relying on imaging tools, and GRAMc, a genome-scale reporter assay method for cis-regulatory modules in embryos and cell lines. To extend his passion to improving human health, he co-founded Ciscovery Bio.

Genomic Profiling Showcase:
Ciscovery Bio
Ciscovery Bio is a non-coding biomarker company that discovers and utilizes cis-regulatory modules for drug development and treatment.

Unlocking the Power of the Noncoding Genome
Ciscovery Bio's mission is to empower drug development and treatment by using the most prevalent noncoding genomic biomarkers, cis-regulatory modules. Jongmin will present Ciscovery Bio's core technology for the discovery of cis-regulatory modules and its key applications.

Biography
Dr. Stanford’s clinical practice is focused on providing consultative services to primary care providers for the purposes of the integration of precision medicine into primary care plans. This approach is novel from its comprehensive nature and practical real-world implementation. Dr. Stanford began his career as a Mechanical/Aerospace Engineer at Texas Instruments in 1982. In 1991, he pivoted into biomedical science and completed the physician-scientist training program (MD/PhD) at UCLA in 1998 and internal medicine residency at UCLA in 2001. Dr. Stanford was one of the pioneers in the field of hospital medicine. In 2002, he founded and led a 25-physician group of private practice hospitalists at Cedars-Sinai Medical Center in Los Angeles and was elected by his peers to be Clinical Chief of General Internal Medicine. He completed Professional Certification in Genetics and Genomics through Stanford University in 2018 and subsequently founded the Beverly Hills Institute for Precision Medicine.

Genomic Profiling Showcase:
Beverly Hills Institute for Precision Medicine
BHIPM provides comprehensive consultative services to primary care providers and their patients for the purposes of integrating precision medicine recommendations into primary care plans.

Precision Medicine Consultation in Primary Care
This presentation provides an overview of the consultative approach taken by BHIPM in using whole genome sequencing and analysis, alongside the patient's comprehensive past medical history, extended family medical history and recent biochemical studies to inform personalized primary care plans.

Biography
Chris is an experienced engineer and manager in the life sciences industry focused on data science, product engineering, and process development. Most recently, he was an engineering manager at Illumina, leading the development of processes for consumables manufacturing across several major platforms, including the HiSeqX nanopatterned flowcell which enabled the $1000 genome.

Genomic Profiling Showcase:
ChromaCode, Inc.
ChromaCode is a software and reagent technology company with a focus on bioinformatics aimed at pioneering advancements in precision diagnostics by integrating reliable biochemical techniques with computational mathematics to enhance performance in testing, at a very low cost.

HDPCR™: Multiplexing Multiplied
ChromaCode expands utility of multiplexed PCR in genomic applications for NIPT and oncology through a unique combination of chemistry and data science. HDPCR™ yields 20-plex in a single well on qPCR and offers exponential utility on digital PCR platforms.

Biography
Joseph Pickrell is the co-founder and CEO of Gencove. With the vision of providing accessible and affordable genomic information, Gencove developed a novel low-pass whole genome sequencing and computational analysis platform for breakthrough biological discovery. Prior to starting Gencove, Dr. Pickrell was a Principal Investigator at the New York Genome Center (NYGC) and Adjunct Assistant Professor in the Department of Biological Sciences at Columbia University. At NYGC, the Pickrell Lab developed novel statistical approaches to transform large-scale genomic data into an improved understanding of human biology and history by understanding natural human variation and molecular and phenotypic consequences. Dr. Pickrell has a Ph.D. in human genetics from the University of Chicago and a B.S. in biology from the University of North Carolina-Chapel Hill. His work has been featured in the New York Times, the Wall Street Journal and has been published in prestigious scientific journals.

Genomic Profiling Showcase:
Gencove
Gencove is making genomic information ubiquitous through high-volume, cost-sensitive whole genome sequencing and computational analysis software. The Gencove platform provides academic, agriculture, biotech, and pharmaceutical companies genomic insights to impact health and sustainability.

Democratizing Genome Sequencing Through Software
Gencove developed high-throughput, cost-effective, low-pass whole genome sequencing with the potential to connect genomic information to phenotypic outcomes. Dr. Joe Pickrell will describe the Gencove technology platform and show how biotech and pharmaceutical companies are using the platform’s genomic insights.

Biography
As Chief Scientific Officer for Clear Labs, I lead the vision and strategy for talented teams of dedicated scientists who make life healthier through the application of genomics and intelligent analytics. From a leadership perspective, I prioritize team culture and empower my team members to maximize their talents and push the bounds of what’s possible. As a scientist and researcher, I have deep insights into the world of health, biotechnology, and next-generation sequencing, and I continue to contribute to the world of academia as an adjunct faculty member at Rutgers University. I want to leave a legacy by raising the quality of life and health of the world’s population. Through my work at Clear Labs, we have made a huge impact on food safety. I aim to expand that impact by using my skills to improve clinical and pharmaceutical genomics and their effectiveness in public health.

Biography
Murray is dedicated to developing precision medicine for common chronic disorders. He has turned this passion into a business opportunity by cofounding the pharmaceutical startup PolygenRx. He is director of the Centre for Complex Disorders and Precision Medicine and Professor of Genetics at the University of Newcastle’s College of Health, Medicine and Wellbeing, School of Biomedical Sciences and Pharmacy. He is also chair of the Hunter Medical Research Institute’s Precision Medicine program. This follows many years in the pharmaceutical and biotechnology industry, including an 8-year role as senior scientist with Johnson and Johnson, which led to a significant commercial development of intellectual property captured in a family of patents. With expertise in bioinformatics, systems biology and high-throughput genomics, Murray has established an internationally recognised research program specialising in complex trait genomics and precision medicine.

Genomic Profiling Showcase:
PolygenRx
PolygenRx is a startup pharmaceutical company using genetics to improve drug discovery and function through precision medicine. Our platform improves drug performance in common disorders by matching them specifically to each patient’s biological variation.

A platform for precision medicine in common disorders
Introducing a precision medicine platform for chronic disorders that matches drugs with their heterogeneous common variant architecture.